Arcuro Medical received FDA 510(k) clearance to market the SuperBall-RC system for use in rotator cuff repair procedures.
SuperBall-RC will enter a limited user release in 2Q25 in anticipation of a full launch in 2H25.
Current rotator cuff re-tear rates following surgery can range from 20% to 40% in patients over 50. Rotator cuff augmentation with biologic or biosynthetic grafts can mitigate this risk but can be technically demanding with current surgical techniques. The new SuperBall-RC product, based on Arcuro’s SuperBall technology platform successfully used in over 5,000 meniscus repairs, addresses this unmet need.
Arcuro Medical received FDA 510(k) clearance to market the SuperBall-RC system for use in rotator cuff repair procedures.
SuperBall-RC will enter a limited user release in 2Q25 in anticipation of a full launch in 2H25.
Current rotator cuff re-tear rates following surgery can range from 20% to 40% in patients over 50. Rotator cuff...
Arcuro Medical received FDA 510(k) clearance to market the SuperBall-RC system for use in rotator cuff repair procedures.
SuperBall-RC will enter a limited user release in 2Q25 in anticipation of a full launch in 2H25.
Current rotator cuff re-tear rates following surgery can range from 20% to 40% in patients over 50. Rotator cuff augmentation with biologic or biosynthetic grafts can mitigate this risk but can be technically demanding with current surgical techniques. The new SuperBall-RC product, based on Arcuro’s SuperBall technology platform successfully used in over 5,000 meniscus repairs, addresses this unmet need.
Copy to clipboard 
